Study estimates 136.8 million U.S. adults are eligible for semaglutide, a popular therapy for diabetes, weight loss, and cardiovascular disease.

Glucagon-like peptide-1 (GLP-1) agonist are a family of medications that help manage blood sugar in patients with type 2 ...

Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side ...

More than half of all adults in the U.S. are eligible for semaglutide (Ozempic, Wegovy, Rybelsus), researchers estimated.

Today it is happening again with GLP1 agonists like Semaglutide with the brand names of Wegovy, Ozempic, and Rybelsus and similar drugs like Moujaro and Zepbound. And just like all the other weight ...

As every student of the Bible knows, you can learn a lot wandering the desert for 40 years. So, yes, (who am I to argue) I’ve learned a lot over my near-four decades navigating our sunny dunes. Still ...

Lexaria Bioscience (LEXX) has engaged a contract research organization to perform the world’s first-ever fluorescently tagged ...

Courts have long deferred to CMS’s decisions on implementation of laws that govern Medicare. The overturning of the Chevron ...

HERSHEY, PA. — GLP-1 weight-loss drugs are having a “mild impact” on The Hershey Co.’s business, president and chief ...

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

Lexaria Bioscience (LEXX) has received lead clinical site human research ethics committee approval that was required before dosing can begin in ...